The Medicines and Healthcare products Regulatory Agency (MHRA) has updated product information for semaglutide, highlighting a very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION). Semaglutide, marketed as Ozempic, Rybelsus, and Wegovy, is prescribed for type 2 diabetes and weight management. NAION, an extremely rare ischemic event, can cause sudden, painless vision loss in one eye. Patients experiencing sudden vision changes or rapid worsening of eyesight should urgently seek emergency care. Dr Alison Cave, MHRA’s Chief Safety Officer, emphasized the importance of monitoring symptoms and reporting incidents via the Yellow Card scheme. The MHRA notes the risk is minimal but advises healthcare professionals and patients to remain vigilant. Guidance on safe use and side effects is available on the MHRA website.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/mhra-updates-guidance-for-semaglutide-prescribers-and-patients
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.